Clinical Trials
45 trialsNivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
City of Hope Medical Center
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
National Cancer Institute (NCI)
NIVIPI-Brain
Fundación GECP
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
WinGlio-ipi
University College, London
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Surgical Nivolumab And Ipilimumab For Recurrent GBM
Dana-Farber Cancer Institute
ABC-X
Melanoma Institute Australia
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
ABC
Melanoma Institute Australia
GlitIpNi
Universitair Ziekenhuis Brussel
Ipilimumab and Nivolumab in Leptomeningeal Metastases
Massachusetts General Hospital
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
National Cancer Institute (NCI)
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Thomas Jefferson University
CheckMate 143
Bristol-Myers Squibb
GVAX Plus Checkpoint Blockade in Neuroblastoma
Dana-Farber Cancer Institute
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
NeAT Glio
University College, London
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
Saint John's Cancer Institute
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
MEMBRAINS
Herlev Hospital
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Baptist Health South Florida
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
H. Lee Moffitt Cancer Center and Research Institute
GRAY-B
Grupo EspaƱol Multidisciplinar de Melanoma
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
University of Michigan Rogel Cancer Center
Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma
University Hospital Tuebingen
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer
National Institutes of Health Clinical Center (CC)
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
IPI+RTS
University Hospital, Lille
NIBIT-M2
Italian Network for Tumor Biotherapy Foundation
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
National Cancer Institute (NCI)